PMID- 32623386 OWN - NLM STAT- MEDLINE DCOM- 20210608 LR - 20210608 IS - 1875-8592 (Electronic) IS - 1574-0153 (Linking) VI - 29 IP - 1 DP - 2020 TI - The clinical significance of interleukin 24 and its potential molecular mechanism in laryngeal squamous cell carcinoma. PG - 111-124 LID - 10.3233/CBM-201441 [doi] AB - Interleukin 24 (IL24) has been documented to be highly expressed in several cancers, but its role in laryngeal squamous cell carcinoma (LSCC) remains unclarified. In this study, to reveal the function and its clinical significance of IL24 in LSCC, multiple detecting methods were used comprehensively. IL24 protein expression was remarkably higher in LSCC (n= 49) than non-cancerous laryngeal controls (n= 26) as detected by in-house immunohistochemistry. Meanwhile, the IL24 mRNA expression was also evaluated based on high throughput data from Gene Expression Omnibus, The Cancer Genome Atlas, ArrayExpress and Oncomine databases. Consistently with the protein level, IL24 mRNA expression level was also predominantly upregulated in LSCC (n= 172) compared to non-cancerous laryngeal tissues (n= 81) with the standard mean difference (SMD) being 1.25 and the area under the curve (AUC) of the summary receiver operating characteristic (sROC) being 0.89 (95% CI = 0.86-0.92). Furthermore, the related genes of IL24 and the differentially expressed genes (DEGs) of LSCC were intersected and sent for Gene ontology (GO) enrichment, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway, and the protein-protein interaction (PPI) analyses. In the GO annotation, the top terms of biological process (BP), cellular component (CC) and molecular function (MF) were extracellular matrix organization, extracellular matrix, cytokine activity, respectively. The top pathway of KEGG was ECM-receptor interaction. The PPI networks indicated the top hub genes of IL24-related genes in LSCC were SERPINE1, TGFB1, MMP1, MMP3, CSF2, and ITGA5. In conclusion, upregulating expression of IL24 may enhance the occurrence of LSCC, which owns prospect diagnostic ability and therapeutic significance in LSCC. FAU - Tang, Xiao-Zhun AU - Tang XZ AD - Department of Head and Neck Tumor Surgery, Guangxi Medical University Cancer Hospital, Guangxi, China. AD - Department of Head and Neck Tumor Surgery, Guangxi Medical University Cancer Hospital, Guangxi, China. FAU - Zhou, Xian-Guo AU - Zhou XG AD - Department of Research, Guangxi Medical University Cancer Hospital, Guangxi, China. AD - Department of Head and Neck Tumor Surgery, Guangxi Medical University Cancer Hospital, Guangxi, China. FAU - Zhang, Xiao-Guohui AU - Zhang XG AD - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Guangxi, China. FAU - Li, Guo-Sheng AU - Li GS AD - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Guangxi, China. FAU - Chen, Gang AU - Chen G AD - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Guangxi, China. FAU - Dang, Yi-Wu AU - Dang YW AD - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Guangxi, China. FAU - Huang, Zhi-Guang AU - Huang ZG AD - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Guangxi, China. FAU - Li, Ming-Xuan AU - Li MX AD - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Guangxi, China. FAU - Liang, Yao AU - Liang Y AD - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Guangxi, China. FAU - Yao, Yu-Xuan AU - Yao YX AD - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Guangxi, China. FAU - Chen, Xiao-Yi AU - Chen XY AD - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Guangxi, China. FAU - Rong, Min-Hua AU - Rong MH AD - Department of Research, Guangxi Medical University Cancer Hospital, Guangxi, China. FAU - Huang, Su-Ning AU - Huang SN AD - Department of Radiotherapy, Guangxi Medical University Cancer Hospital, Guangxi, China. LA - eng PT - Journal Article PL - Netherlands TA - Cancer Biomark JT - Cancer biomarkers : section A of Disease markers JID - 101256509 RN - 0 (Biomarkers, Tumor) RN - 0 (CSF2 protein, human) RN - 0 (ITGA5 protein, human) RN - 0 (Integrins) RN - 0 (Interleukins) RN - 0 (MicroRNAs) RN - 0 (Plasminogen Activator Inhibitor 1) RN - 0 (SERPINE1 protein, human) RN - 0 (TGFB1 protein, human) RN - 0 (Transforming Growth Factor beta1) RN - 0 (interleukin-24) RN - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor) RN - EC 3.4.24.17 (MMP3 protein, human) RN - EC 3.4.24.17 (Matrix Metalloproteinase 3) RN - EC 3.4.24.7 (MMP1 protein, human) RN - EC 3.4.24.7 (Matrix Metalloproteinase 1) SB - IM MH - Biomarkers, Tumor/*genetics MH - Carcinoma, Squamous Cell/diagnosis/*genetics/pathology MH - Computational Biology MH - Female MH - Gene Expression Regulation, Neoplastic/genetics MH - Gene Regulatory Networks/genetics MH - Granulocyte-Macrophage Colony-Stimulating Factor/genetics MH - Humans MH - Integrins/genetics MH - Interleukins/*genetics MH - Male MH - Matrix Metalloproteinase 1/genetics MH - Matrix Metalloproteinase 3/genetics MH - MicroRNAs MH - Middle Aged MH - Plasminogen Activator Inhibitor 1/genetics MH - Protein Interaction Maps/genetics MH - Signal Transduction/genetics MH - Squamous Cell Carcinoma of Head and Neck/diagnosis/*genetics/pathology/therapy MH - Transforming Growth Factor beta1/genetics OTO - NOTNLM OT - Interleukin 24 OT - RNA-sequencing OT - immunohistochemistry OT - laryngeal squamous cell carcinoma OT - microarray EDAT- 2020/07/06 06:00 MHDA- 2021/06/09 06:00 CRDT- 2020/07/06 06:00 PHST- 2020/07/06 06:00 [pubmed] PHST- 2021/06/09 06:00 [medline] PHST- 2020/07/06 06:00 [entrez] AID - CBM201441 [pii] AID - 10.3233/CBM-201441 [doi] PST - ppublish SO - Cancer Biomark. 2020;29(1):111-124. doi: 10.3233/CBM-201441.